Renal targeted protein therapeutics in experimental overt heart failure with renal dysfunction

por Chen, Horng H, Cataliotti, Alessandro, Martin, Fernando L, Schirger, John A, Burnett, John C
Publicado 2009

The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation

por Schirger, John A, Chen, Horng H, Slusser, Josh, Hodge, David, Heublein, Denise, Cataliotti, Alessandro, Sandberg, Sharon, Burnett, John C
Publicado 2009

Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without redu...

por Costello-Boerrigter, Lisa C, Schirger, John A, Miller, Wayne L, Boerrigter, Guido, Chen, Horng H, Kempf, Ruth, Lee, Candace Y, Burnett, John C
Publicado 2011

Pulmonary function assessment post‐left ventricular assist device implantation

por Sajgalik, Pavol, Kim, Chul‐Ho, Stulak, John M., Kushwaha, Sudhir S., Maltais, Simon, Joyce, David L., Joyce, Lyle D., Johnson, Bruce D., Schirger, John A.
Publicado 2018

Routine Laboratory Biomarkers As Prognostic Indicators of Cardiac Sarcoidosis Outcomes

por Kolluri, Nikhil, Schmidt, Tyler J., Elwazir, Mohamed Y., Kapa, Suraj, Abou Ezzeddine, Omar F., Bois, John P., Schirger, John A., Rosenbaum, Andrew N., Cooper, Leslie T.
Publicado 2022

A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure

por Kawakami, Rika, Lee, Candace Y.W., Scott, Christopher, Bailey, Kent R., Schirger, John A., Chen, Horng H., Benike, Sherry L., Cannone, Valentina, Martin, Fernando L., Sangaralingham, S. Jeson, Ichiki, Tomoko, Burnett, John C.
Publicado 2018